2020 - 1
|
Phase 2 multiple-dose study of an FcRn inhibitor, rozanolixizumab, in patients with primary immune thrombocytopenia |
Robak Tadeusz , Kazmierczak Maciej , Jarque Isidro , Musteaţă Vasile Gheorghe, Trelinski Jacek , Cooper Nichola , Kiessling Peter C. , Massow Ute , Woltering Franz , Snipes Rose G. , Ke Juan , Langdon Grant , Bussel James Bruce , Jolles Stephen |
1 Medical University of Lodz, 2 Copernicus Memorial Hospital, Lodz, 3 Poznan University of Medical Sciences, 4 La Fe University and Polytechnic Hospital, Valencia, 5 Instituto de Salud Carlos III, 6 Institute of Oncology, 7 Imperial College Healthcare National Health Service Trust, London, 8 Union Chimique Belge (UCB) Pharma, Monheim-am-Rhein, 9 UCB Pharma, Raleigh, 10 UCB Pharma, Slough, 11 PTx Solutions Ltd., London, 12 Weill Cornell Medicine, New York, 13 University Hospital of Wales, Cardiff |
Blood Advances |
Nr. 4(17) / 2020 / ISSN 2473-9537 |
Disponibil online 15 March, 2021 |
-----------------------------------------------------------------------------------------------------------------------------------